Portfolio Tracker
Alle Depots an einem Ort. Dein Gesamtvermögen immer im Blick, tiefgründige Renditeanalysen und Dividendenplaner.
Anzeige
EQS-News

Galimedix announces participation at fall 2026 investor, partnering, and scientific conferences 22.09.2026, 13:00 Uhr von EQS News Jetzt kommentieren: 0

EQS-News: Galimedix, Inc. / Key word(s): Conference
Galimedix announces participation at fall 2026 investor, partnering, and scientific conferences

22.09.2026 / 13:00 CET/CEST
The issuer is solely responsible for the content of this announcement.


Galimedix announces participation at fall 2026 investor, partnering, and scientific conferences

Kensington, MD, USA and Munich/Martinsried, Germany, September 22, 2026 – Galimedix Therapeutics, Inc. (“Galimedix”), a Phase 2 clinical-stage biotechnology company developing novel oral and topical neuroprotective therapies with the potential to revolutionize the treatment of serious brain and eye diseases, today announced that the company will participate in a variety of events this fall in both the U.S. and Europe.

Partnering and Investor Events

LSX Congress USA
Date:
September 23 - 24
Location: Boston, MA, USA

H.C. Wainwright Biotech on Tap
Date
: October 1- 3
Location: Munich, Germany

26th Annual Biotech in Europe Forum #Sachs_BEF
Date
: October 7 - 8
Location: Basel, Switzerland
Company Presentation: October 7, 2:45 pm (CEST), Track B, Room "Ballroom"
Panel: Neuroscience Innovation panel October 7; 4:35 pm (CEST)
Panelist & Presenter: Alexander Gebauer, MD, PhD, Co-Founder and Executive Chairman of Galimedix

BioFuture
Date
: October 27 - 28
Location: New York, NY, USA
Company Presentation: not yet announced
Panel: Spotlight Panel 4B - Rewiring Minds: Breakthroughs in Brain & CNS Health October 28; 10:00 am (EDT)
Panelist & Presenter: Alexander Gebauer, MD, PhD, Co-Founder and Executive Chairman of Galimedix

BIO-Europe
Date:
November 9 - 11
Location: Cologne, Germany

Scientific Conferences

26th EURETINA Congress
Date:
October 1-4
Location: Vienna, Austria
Several oral presentations and e-posters related to Phase 2 eDREAM study in geographic atrophy
More information on the data presented at Euretina can be found here.

American Academy of Ophthalmology Annual Meeting
Date:
October 9 - 12
Location: New Orleans, LA, USA

Clinical Trials on Alzheimer's Disease (CTAD) Conference
Date:
November 16 - 19
Location: Boston, MA, USA
Poster Title: SAPHARY Phase 2a study to investigate the safety, efficacy, and pharmacokinetics of GAL-101 salt as oral treatment for patients with mild to moderate Alzheimer's disease

Attendees interested in meeting with the Galimedix team can schedule a meeting via the respective conference's partnering system, e-Mail or LinkedIn.

About Galimedix Therapeutics, Inc.

Galimedix is a Phase 2 clinical-stage private company developing novel oral and topical neuroprotective therapies with the potential to revolutionize the treatment of serious eye and brain diseases. Founded by a seasoned and highly dedicated team of bio-entrepreneurs, pharmaceutical executives and scientists, Galimedix’s groundbreaking small molecules offer the hope of changing the course of disease where amyloid beta (Aβ) plays a role, such as in dry age-related macular degeneration (AMD), glaucoma and Alzheimer’s disease - Galimedix’s initial areas of focus. For more information, visit www.galimedix.com and follow us on LinkedIn.
 

Contact
Alexander Gebauer, MD, PhD
Galimedix Therapeutics, Inc.
Co-founder and Executive Chairman
info@galimedix.com
Media inquiries
Anne Hennecke
MC Services AG
Tel: +49 (0) 170 7134018
galimedix@mc-services.eu
U.S.
Laurie Doyle
Tel: +1-339-832-0752

 



22.09.2026 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group.
The issuer is solely responsible for the content of this announcement.

The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
View original content: EQS News


2403194  22.09.2026 CET/CEST

Kommentare (0) ... diskutiere mit.
k.A. k.A. k.A. k.A.
k.A. k.A. k.A. k.A.
k.A. k.A. k.A. k.A.
Weitere News

Gestern 23:37 Uhr • Artikel • dpa

Gestern 22:22 Uhr • Artikel • dpa

Gestern 22:08 Uhr • Artikel • dpa

Gestern 14:05 Uhr • Artikel • dpa-AFX

Gestern 13:57 Uhr • Artikel • dpa-AFX

Gestern 13:57 Uhr • Artikel • dpa-AFX

Schreib den ersten Kommentar!

Dis­clai­mer: Die hier an­ge­bo­te­nen Bei­trä­ge die­nen aus­schließ­lich der In­for­ma­t­ion und stel­len kei­ne Kauf- bzw. Ver­kaufs­em­pfeh­lung­en dar. Sie sind we­der ex­pli­zit noch im­pli­zit als Zu­sich­er­ung ei­ner be­stim­mt­en Kurs­ent­wick­lung der ge­nan­nt­en Fi­nanz­in­stru­men­te oder als Handl­ungs­auf­for­der­ung zu ver­steh­en. Der Er­werb von Wert­pa­pier­en birgt Ri­si­ken, die zum To­tal­ver­lust des ein­ge­setz­ten Ka­pi­tals füh­ren kön­nen. Die In­for­ma­tion­en er­setz­en kei­ne, auf die in­di­vi­du­el­len Be­dür­fnis­se aus­ge­rich­te­te, fach­kun­di­ge An­la­ge­be­ra­tung. Ei­ne Haf­tung oder Ga­ran­tie für die Ak­tu­ali­tät, Rich­tig­keit, An­ge­mes­sen­heit und Vol­lständ­ig­keit der zur Ver­fü­gung ge­stel­lt­en In­for­ma­tion­en so­wie für Ver­mö­gens­schä­den wird we­der aus­drück­lich noch stil­lschwei­gend über­nom­men. Die Mar­kets In­side Me­dia GmbH hat auf die ver­öf­fent­lich­ten In­hal­te kei­ner­lei Ein­fluss und vor Ver­öf­fent­lich­ung der Bei­trä­ge kei­ne Ken­nt­nis über In­halt und Ge­gen­stand die­ser. Die Ver­öf­fent­lich­ung der na­ment­lich ge­kenn­zeich­net­en Bei­trä­ge er­folgt ei­gen­ver­ant­wort­lich durch Au­tor­en wie z.B. Gast­kom­men­ta­tor­en, Nach­richt­en­ag­en­tur­en, Un­ter­neh­men. In­fol­ge­des­sen kön­nen die In­hal­te der Bei­trä­ge auch nicht von An­la­ge­in­te­res­sen der Mar­kets In­side Me­dia GmbH und/oder sei­nen Mit­ar­bei­tern oder Or­ga­nen be­stim­mt sein. Die Gast­kom­men­ta­tor­en, Nach­rich­ten­ag­en­tur­en, Un­ter­neh­men ge­hör­en nicht der Re­dak­tion der Mar­kets In­side Me­dia GmbH an. Ihre Mei­nung­en spie­geln nicht not­wen­di­ger­wei­se die Mei­nung­en und Auf­fas­sung­en der Mar­kets In­side Me­dia GmbH und de­ren Mit­ar­bei­ter wie­der. Aus­führ­lich­er Dis­clai­mer